Maxim downgraded Akari Therapeutics to Hold from Buy without a price target. The selloff post the partnership with WuXi XDC is due in part due to Akari's additional capital needs and continued pressure following the ratio change that took effect on March 31, the analyst tells investors in a research note. With the shares near an all-time low and a market capitalization below $5M, Maxim believes the company's risks are elevated in an already challenging financing environment. It cites funding risk for the downgrade.
